Breaking News Instant updates and real-time market news.

ULTA

Ulta Beauty

$245.00

4.07 (1.69%)

, MTCH

Match Group

$42.58

0.6 (1.43%)

10:19
12/19/18
12/19
10:19
12/19/18
10:19

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Buy at Citi. 2. Match Group (MTCH) initiated with a Hold at SunTrust. 3. ShotSpotter (SSTI) initiated with an Outperform at Baird. 4. Okta (OKTA) initiated with a Neutral at DA Davidson. 5. Cellectis (CLLS) initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ULTA

Ulta Beauty

$245.00

4.07 (1.69%)

MTCH

Match Group

$42.58

0.6 (1.43%)

SSTI

ShotSpotter

$30.30

1.12 (3.84%)

OKTA

Okta

$66.09

3.32 (5.29%)

CLLS

Cellectis

$18.35

0.6 (3.38%)

  • 08

    Jan

  • 09

    Jan

  • 16

    Jan

ULTA Ulta Beauty
$245.00

4.07 (1.69%)

12/19/18
SBSH
12/19/18
INITIATION
Target $135
SBSH
Buy
Ulta Beauty initiated with a Buy at Citi
Citi analyst Beth Kite started Ulta Beauty with a Buy rating and $135 price target. Target $135. The analyst sees a buying opportunity at current valuation levels given her favoranle view of the company's outlook.
12/07/18
COWN
12/07/18
NO CHANGE
Target $340
COWN
Outperform
Ulta Beauty weakness a buying opportunity, says Cowen
Cowen analyst Oliver Chen views any weakness in Ulta Beauty following its Q3 results as a long-term buying opportunity. He noted investors may be disappointed in the gross margins erosion, but he believes it was due to higher unplanned clearance activity. He added that the company's guidance was affirmed and the strong fundamentals remain intact. Chen reiterated his Outperform rating and $340 price target on Ulta Beauty shares.
12/11/18
OPCO
12/11/18
NO CHANGE
Target $340
OPCO
Outperform
Ulta Beauty price target lowered to $340 from $375 at Oppenheimer
Oppenheimer analyst Rupesh Parikh lowered his price target for Ulta Beauty to $340 from $375 to reflect the re-rating of high quality growth stories and the potential for less earnings upside. Since the company's report, shares are now down 16%, but while the analyst believes some of the pullback is justified, he overall views the selloff as "meaningfully overdone." Investors were positioned for upside, and instead margins surprised to the downside and the Q4 comp guide came in a bit light, he adds. Parikh reiterates an Outperform rating on the shares.
12/14/18
LOOP
12/14/18
NO CHANGE
Target $265
LOOP
Hold
Ulta Beauty price target lowered to $265 from $300 at Loop Capital
Loop Capital analyst Anthony Chukumba lowered his price target on Ulta Beauty to $265 and kept his Hold rating to reflect the "weakening sentiment in the retail industry". The analyst points to his pre-holiday beauty products pricing survey as a positive however, saying that most retailers "continue to largely adhere to manufacturer's suggested retail prices, with discounting still non-existent." Chukumba adds that Ulta Beauty's current valuation of 20-times his expected forward earnings is a discount relative to its historical average, justifiable by the company's "slowing comparable sales and square footage growth."
MTCH Match Group
$42.58

0.6 (1.43%)

12/18/18
RHCO
12/18/18
INITIATION
RHCO
Hold
Match Group initiated with a Hold at SunTrust
SunTrust analyst Youssef Squali initiated Match Group with a Hold rating and $47 price target. The analyst said he expects growth to slow in 2019/2020 after Tinder Gold created a change in the marketplace, and added that he feels the stock is fairly valued.
12/18/18
RHCO
12/18/18
INITIATION
Target $47
RHCO
Hold
Match Group initiated with a Hold at SunTrust
SunTrust started Match Group with a Hold rating and $47 price target.
11/28/18
MACQ
11/28/18
INITIATION
MACQ
Outperform
Match Group initiated with an Outperform at Macquarie
12/11/18
SRCH
12/11/18
INITIATION
SRCH
Hold
Match Group initiated with a Hold at Summit Insights
Summit Insights initiated Match Group with a Hold and $45 price target.
SSTI ShotSpotter
$30.30

1.12 (3.84%)

11/19/18
IMPC
11/19/18
UPGRADE
Target $49
IMPC
Outperform
Imperial Capital upgrades ShotSpotter to Outperform after recent selloff
Imperial Capital analyst Saliq Khan upgraded ShotSpotter to Outperform from In-Line while lowering his price target for the shares to $49 from $54. The upgrade reflects the analyst's positive view on the company's growth and profitability outlook, its recent software acquisition, and the better than expected Q3 results. The analyst believes the stock may not be undervalued following the recent selloff. Further, a slowdown in the U.S. economy would have a minimal on ShotSpotter's growth, particularly as compared to other non-critical service and solution providers, in the near-to-medium timeframe, Khan tells investors in a research note.
11/19/18
IMPC
11/19/18
UPGRADE
IMPC
Outperform
ShotSpotter upgraded to Outperform from In-Line at Imperial Capital
12/03/18
NATL
12/03/18
INITIATION
NATL
Buy
ShotSpotter initiated with a Buy at National Securities
12/18/18
BARD
12/18/18
INITIATION
Target $41
BARD
Outperform
ShotSpotter initiated with an Outperform at Baird
Baird initiated ShotSpotter with an Outperform rating and $41 price target.
OKTA Okta
$66.09

3.32 (5.29%)

12/18/18
DADA
12/18/18
INITIATION
Target $62
DADA
Neutral
Okta initiated with a Neutral at DA Davidson
DA Davidson analyst Rishi Jaluria initiated Okta with a Neutral rating and a price target of $62. The analyst is positive on the "value proposition" of the company, along with its "market leadership position and rapid growth", but believes that its stock price is "fully valued" at 12-times enterprise value to expected 2020 revenue. Jaluria adds that he awaits a "better entry point" before becoming more constructive on Okta stock.
12/10/18
GUGG
12/10/18
INITIATION
Target $79
GUGG
Buy
Okta initiated with a Buy at Guggenheim
Guggenheim analyst Imtiaz Koujalgi started Okta with a Buy rating and $79 price target. The analyst also added the shares to Guggenheim's Best Idea List.
12/10/18
DBAB
12/10/18
NO CHANGE
DBAB
Buy
Okta well on-track to grow revenue over 50% in FY19, says Deutsche Bank
Deutsche Bank analyst Gray Powell reiterates a Buy rating on Okta after meeting with Alex Salazar, the company's VP of Product Strategy and Catherine Buan, head of investor relations. The analyst says the insights he picked up on demand trends were "positive on multiple fronts" and that he came away with a "high degree of confidence" in the company's drivers of long-term growth. Okta is well on-track to grow revenue in excess of 50% in fiscal 2019, Powell tells investors in a research note. Further, he feels "very confident" in the company's forecasts for fiscal 2020 that call for growth of 30%-33% year-over-year.
12/06/18
WBLR
12/06/18
NO CHANGE
WBLR
Outperform
Okta reached positive cash flow for first time, says William Blair
William Blair analyst Jonathan Ho says Okta last night reported "another stellar" quarter and reached positive cash flow for the first time. While Okta raised guidance for fiscal 2019 and provided a preliminary top-line outlook for fiscal 2020 above the consensus, the guidance remains "relatively conservative given the strong demand driving the quarter and strong execution," Ho tells investors in a post-earnings research note. He believes Okta is being prudent in setting expectations low. Further, based on the strong quarterly results, he believes "evidence continues to mount that the company is becoming the dominant player in identity." Ho keeps an Outperform rating on Okta.
CLLS Cellectis
$18.35

0.6 (3.38%)

07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Barclays starts Cellectis with Overweight rating, $50 price target
Barclays analyst Gena Wang initiated coverage of Cellectis S.A. with an Overweight rating and $50 price target. Following "impressive data" and several approvals of personalized autologous CAR-T cell therapies in various blood cancers, universal off-the-shelf allogeneic CAR-T would be future therapeutic approach with improved timeline, costs and homogeneity, Wang tells investors in a research note. As a leader in allo-CART with its proprietary Talen gene editing technology, Cellectis is the only company with clinical experience, on two programs, the analyst adds. She believes the company has a "strong" pipeline of allogeneic CAR-Ts targeting advanced blood cancers.
07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Cellectis initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Cellectis with an Overweight rating and $50 price target.
12/19/18
GSCO
12/19/18
INITIATION
Target $25
GSCO
Neutral
Cellectis initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter started Cellectis with a Neutral rating and $25 price target. The analyst says it is time for the company to execute on its gene editing platform technology and prefers to remain on the sidelines pending clinical data readouts in 2019.
06/12/18
OPCO
06/12/18
NO CHANGE
Target $44
OPCO
Outperform
Cellectis price target raised to $44 from $40 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Cellectis to $44 from $40 after the company announced that the FDA approved its IND filing for UCART22 following a 30-day review period. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

XLNX

Xilinx

$96.18

3.4 (3.66%)

, INTC

Intel

$52.06

0.95 (1.86%)

20:45
10/13/19
10/13
20:45
10/13/19
20:45
Upgrade
Xilinx, Intel rating change at Nomura Instinet »

Xilinx upgraded to Buy…

XLNX

Xilinx

$96.18

3.4 (3.66%)

INTC

Intel

$52.06

0.95 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 20

    Nov

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated at Piper Jaffray »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

CNCE

Concert Pharmaceuticals

$5.85

(0.00%)

15:29
10/13/19
10/13
15:29
10/13/19
15:29
Hot Stocks
Concert Pharmaceuticals presents Phase 2 data in Alopecia Areata »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$76.14

0.38 (0.50%)

15:23
10/13/19
10/13
15:23
10/13/19
15:23
Hot Stocks
Incyte announces 52-week results from Phase 2 study of Ruxolitinib cream »

Incyte announced 52-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.